



Autolus Therapeutics to Participate in Conferences During April 2022

March 29, 2022

- Wells Fargo Annual Biotech Forum on April 12 and 13 -

- 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET -

- 14th Kempen Life Sciences Conference on April 21 - presentation time to be confirmed on the Autolus website -

LONDON, March 29, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in three upcoming investor conferences. An audio webcast of any presentations will be available live. You can access the webcasts via the [Events](#) section of the Autolus website. An archived version will also be available through the Company's website for a limited time following the conference.

About Autolus Therapeutics plc

Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the Company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information, please visit www.autolus.com.

Contact:

Olivia Manser
+44 (0) 7780 471568
o.manser@autolus.com

Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan

S.A. Noonan Communications
+1-917-513-5303
susan@sanoonan.com